Exact Sciences Corp
EXASExact Sciences Corp (EXAS) is a molecular diagnostics company focused on developing and commercializing innovative tests for cancer detection and prevention. The company's flagship product, Cologuard, is a non-invasive stool-based screening test for colorectal cancer. Exact Sciences also invests in advancing genomics and liquid biopsy technologies to improve early cancer detection and patient management.
Company News
Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.
Abbott Laboratories announced a $21 billion acquisition of Exact Sciences, a cancer diagnostic specialist, to expand its diagnostics business and enter the cancer screening market with innovative products like Cologuard.
The Pre-Dx oncology market is entering a high-growth phase, driven by breakthrough non-invasive cancer detection technologies like liquid biopsy and multi-cancer early detection tests. The market is expected to generate substantial revenue growth, with North America leading and Asia Pacific showing the fastest growth potential.
Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.
